ITASCA, IL--(Marketwire - Nov 27, 2012) - AtCor Medical (ASX: ACG), the developer and marketer of SphygmoCor® systems, which non-invasively measures central aortic blood pressure and arterial ...
There are still few large cohort studies comparing the prospective value of central versus peripheral (brachial) pressures, but a number of small to medium size studies have demonstrated the value of ...
Several parameters of central arterial blood pressure and wave reflection characteristics have demonstrated value as independent predictors of future cardiovascular ...
CONNEQT Health has taken a major step forward in its transformation from a medical device company to a scalable cloud-based platform business by lodging an application with the US Food and Drug ...
Conneqt Health Ltd (ASX:CQT) has taken a key step toward expanding its cardiovascular health technology platform, lodging an FDA Pre-Submission package for SphygmoCor Cloud, its next-generation ...
CardieX Limited, an ASX listed global health technology company, announced that its subsidiary Atcor was granted a new patent by the European Patent Office (EPO) for the company's proprietary ...
Rajiv Gandhi Government General Hospital (GH) will soon undertake a study to test the effectiveness of a new apparatus — SphygmoCor — used for measuring central artery pressure in a non-invasive ...
AtCor Medical Limited, the developer and marketer of the SphygmoCor system which measures central blood pressures and arterial stiffness non-invasively, has signed a new contract to supply SphygmoCor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results